Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2

Solicitation No.

DARPA-PS-26-124

Notice Type

Solicitation

Posted Date

May 28, 2026

Response Deadline

June 24, 2026

NAICS Code

541714AI guide

PSC / Class Code

AC12

Contract Code

97AE

Issuing Office

DEF ADVANCED RESEARCH PROJECTS AGCY

Sub-Agency

DEFENSE ADVANCED RESEARCH PROJECTS AGENCY

Agency

DEPT OF DEFENSE

Primary Contact

BAA Coordinator

City

ARLINGTON

State

VA

ZIP Code

222032114

AI Product/Service

both

UPDATE: Clarification regarding program coordination across Task Areas (Sections 1.3 and 2.5), clarification of the acquisition strategy (Section 2.1), and removal of broken links to tables, figures, and footnotes. The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.

1. May 28, 2026Posted Date
2. June 24, 2026Proposals / Responses Due